Immune Checkpoint Inhibitor Myocarditis and Left Ventricular Systolic Dysfunction
Chen Y, Dolladille C, Rao A, Palaskas N, Deswal A, Lehmann L, Cautela J, Courand P, Hayek S, Zhu H, Cheng R, Alexandre J, Baldassarre L, Roubille F, Laufer-Perl M, Asnani A, Ederhy S, Tamura Y, Francis S, Gaughan E, Johnson D, Flint D, Rainer P, Bailly G, Ewer S, Aras M, Arangalage D, Cariou E, Florido R, Peretto G, Zadok O, Akhter N, Narezkina A, Levenson J, Liu Y, Crusz S, Issa N, Piriou N, Leong D, Sandhu S, Turker I, Moliner P, Obeid M, Heinzerling L, Chang W, Stewart A, Venkatesh V, Du Z, Yadavalli A, Kim D, Chandra A, Zhang K, Power J, Moslehi J, Salem J, Zaha V, Registry I. Immune Checkpoint Inhibitor Myocarditis and Left Ventricular Systolic Dysfunction. JACC CardioOncology 2025, 7: 234-248. PMID: 40246381, PMCID: PMC12046861, DOI: 10.1016/j.jaccao.2025.01.020.Peer-Reviewed Original ResearchLeft ventricular ejection fractionImmune checkpoint inhibitorsPredictors of left ventricular ejection fractionAll-Cause MortalityHeart failureAssociated with 30-day all-cause mortalityDocumented LVEFAssociated with left ventricular ejection fractionReduced left ventricular ejection fractionImmune checkpoint inhibitor initiationImmune checkpoint inhibitor myocarditisHistory of heart failurePre-existing heart failureTransforming cancer treatmentVentricular ejection fractionCox proportional hazards modelsBody mass indexMultivariate logistic regressionTime of hospitalizationProportional hazards modelCheckpoint inhibitorsMyositis symptomsChest radiationCardiotoxic therapiesEjection fraction
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply